Communication| Volume 23, ISSUE 8, P788-790, December 2001

Oligonucleotides against a splicing enhancer sequence led to dystrophin production in muscle cells from a Duchenne muscular dystrophy patient

      Duchenne muscular dystrophy (DMD) is a rapid, progressive disease that usually results in death at around the age of 20, while Becker muscular dystrophy (BMD) is a clinically less severe form of the disease that often has only slight debilitating effects. Deletion mutations in the dystrophin gene have been identified in two thirds of DMD/BMD cases and the clinical progression of DMD or BMD patients can be predicted from whether the deletion disrupts or maintains the translational reading frame of the mRNA [
      • Monaco A.P.
      • Bertelson C.J.
      • Liechti-Gallati S.
      • Moser H.
      • Kunkel L.M.
      An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus.
      ]. In spite of the progress of molecular understanding of DMD, any effective treatment has not yet been established.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Brain and Development
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Monaco A.P.
        • Bertelson C.J.
        • Liechti-Gallati S.
        • Moser H.
        • Kunkel L.M.
        An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus.
        Genomics. 1988; 2: 90-95
        • Matsuo M.
        Duchenne/Becker muscular dystrophy: from molecular diagnosis to gene therapy.
        Brain Dev. 1996; 18: 167-172
        • Wilton S.D.
        • Lloyd F.
        • Carville K.
        • Fletcher S.
        • Honeyman K.
        • Agrawal S.
        • et al.
        Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides.
        Neuromusc Disord. 1999; 9: 330-338
        • Mann C.J.
        • Honeyman K.
        • Cheng A.J.
        • Ly T.
        • Lloyd F.
        • Fletcher S.
        • et al.
        Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse.
        Proc Natl Acad Sci USA. 2001; 98: 42-47
        • Takeshima Y.
        • Nishio H.
        • Sakamoto H.
        • Nakamura H.
        • Matsuo M.
        Modulation of in vitro splicing of the upstream intron by modifying an intra-exon sequence which is deleted from the dystrophin gene in dystrophin Kobe.
        J Clin Invest. 1995; 95: 515-520
        • Pramono Z.A.
        • Takeshima Y.
        • Alimsardjono H.
        • Ishii A.
        • Takeda S.
        • Matsuo M.
        Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxynucleotide complementary to an exon recognition sequence.
        Biochem Biophys Res Commun. 1996; 226: 445-449
        • Blau H.M.
        • Webster C.
        Isolation and characterization of human muscle cells.
        Proc Natl Acad Sci USA. 1981; 78: 5623-5627
        • Thanh L.T.
        • thi Man N.
        • Helliwell T.R.
        • Morris G.E.
        Characterization of revertant muscle fibers in Duchenne muscular dystrophy, using exon-specific monoclonal antibodies against dystrophin.
        Am J Hum Genet. 1995; 56: 725-731
        • Fanin M.
        • Danieli G.A.
        • Cadaldini M.
        • Miorin M.
        • Vitiello L.
        • Angelini C.
        Dystrophin-positive fibers in Duchenne dystrophy: origin and correlation to clinical course.
        Muscle Nerve. 1995; 18: 1115-1120
        • Winnard A.V.
        • Mendell J.R.
        • Prior T.W.
        • Florence J.
        • Burghes H.M.
        Frameshift deletions of exons 3–7 and revertant fibers in Duchenne muscular dystrophy: mechanisms of dystrophin production.
        Am J Hum Genet. 1995; 56: 158-166
        • Passos-Bueno M.R.
        • Vainzof M.
        • Marie S.K.
        • Zatz M.
        Half the dystrophin gene is apparently enough for a mild clinical course: confirmation of its potential use for gene therapy.
        Hum Mol Genet. 1994; 3: 919-922
        • van Deutekom J.C.
        • Bremmer-Bout M.
        • Janson A.A.
        • Ginjaar I.B.
        • Baas F.
        • den Dunnen J.T.
        • et al.
        Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells.
        Hum Mol Genet. 2001; 10: 1547-1554